Singapore-based Nanyang Biologics has entered a $1.5 billion business combination agreement with Nasdaq-listed RF Acquisition Corp II to facilitate its public listing. The company is building a hybrid platform that combines machine learning with natural compound libraries to revolutionize drug discovery. Nanyang claims ownership of one of the world's largest AI-curated collections of bioactive compounds, aiming to accelerate therapeutics development through this innovative approach.